Lakeside Holding Limited (LSH)

In the past six months, Lakeside Holding Ltd. announced a delay in filing its 10-Q, appointed Mr. Yang Li as joint Chief Executive Officer, partnered with Huiyu Pharmaceutical to revolutionize oncology drug distribution, signed a $1.5 million sales agreement with a Sinopharm Group subsidiary, strengthened its market position in China's pharmaceutical logistics with key Sinopharm (Hubei) contracts, and was scheduled to present at The Benchmark Company's Discovery One-on-One Investor Conference.

Information regarding the specific demand seasonality for Lakeside Holding Ltd.'s products and services was not explicitly available. However, its freight and logistics services could be influenced by global trade patterns, holiday shopping seasons, and manufacturing cycles, while its pharmaceutical distribution in China might be subject to healthcare demand trends within that region.

Lakeside Holding Ltd. (LSH) is a U.S.-based integrated cross-border supply chain solution provider in the industrials sector, focusing on integrated freight and logistics, with a strategic emphasis on the Asian market, particularly China and South Korea. The company's core business includes cross-border freight and logistics services through American Bear Logistics, offering customized ocean and airfreight solutions, and pharmaceutical distribution in China through Hupan Pharmaceutical, supplying pharmaceuticals to distributors, hospitals, and clinics. The company was founded in 2018 and is headquartered in Itasca, Illinois.

Lakeside Holding Ltd. operates in the United States and Asia. In the U.S., American Bear Logistics has hubs in Chicago, Dallas, Los Angeles, and New York, along with warehousing and distribution centers in Illinois and Texas. Its Asian focus includes China and South Korea, particularly through its pharmaceutical distribution arm in China.

Specific details regarding Lakeside Holding Ltd.'s brand reputation were not explicitly detailed. However, the company's press releases indicate ongoing business developments and partnerships, particularly in the pharmaceutical sector in China.

Information regarding major institutional and individual owners of Lakeside Holding Ltd. was not readily available.